Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
- 1 February 1983
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 15 (S1) , 67S-70S
- https://doi.org/10.1111/j.1365-2125.1983.tb02110.x
Abstract
1 We have assessed the thromboxane synthetase inhibitor, dazoxiben (UK 37248), during dialysis in a double‐blind, placebo‐controlled crossover study. 2 Thromboxane generation was markedly inhibited, and there was an increase in serum 6‐keto prostaglandin F1 alpha levels during active treatment studies. 3 We were unable to demonstrate any reduction of platelet activation, or dialyser fibrin deposition, nor were heparin requirements altered by the drug. 4 Dazoxiben had no adverse effects.Keywords
This publication has 7 references indexed in Scilit:
- THROMBOXANE SYNTHETASE INHIBITION AS ANTITHROMBOTIC STRATEGYThe Lancet, 1981
- PLATELET PROTECTION AND HEPARIN SPARING WITH PROSTACYCLIN DURING REGULAR DIALYSIS THERAPYThe Lancet, 1980
- REDUCTION OF DIALYZER FIBRIN DEPOSITION WITH SULPHINPYRAZONE1979
- Physiological and Pharmacological Roles of ProstaglandinsAnnual Review of Pharmacology, 1975
- Prostaglandin D2 inhibits the aggregation of human plateletsThrombosis Research, 1974
- REDUCTION OF THROMBUS FORMATION ON DIALYSER MEMBRANES BY ASPIRIN AND RA 233The Lancet, 1972
- Haemostatic Changes during Dialysis Associated with Thrombus Formation on Dialysis MembranesBMJ, 1972